AUTHOR=Lu Guimei , Li Qingqing 

TITLE=The controlling nutritional status score as a predictor of survival in hematological malignancies: a systematic review and meta-analysis

JOURNAL=Frontiers in Nutrition

VOLUME=11

YEAR=2024

URL=https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2024.1402328

DOI=10.3389/fnut.2024.1402328

ISSN=2296-861X

ABSTRACT=<sec id="sec1"><title>Objective</title><p>The controlling nutritional status score (CONUT) has been widely used for ascertaining the prognosis of various cancers. However, its use in patients with hematological malignancies remains unclear. This review examined evidence on the utility of CONUT as a prognostic marker for patients with hematological malignancies.</p></sec><sec id="sec2"><title>Methods</title><p>All cohort studies that examined the association between CONUT and outcomes of hematological malignancies and were published on the databases of Embase, Scopus, CENTRAL, Web of Science, and PubMed were searched from the inception of the databases to 30 January 2024. The primary outcome was overall survival (OS), and the secondary outcome was progression-free survival (PFS).</p></sec><sec id="sec3"><title>Results</title><p>A total of 23 studies were available for review. A meta-analysis of 22 studies showed that high CONUT was significantly associated with poor OS in patients with hematological malignancies (HR: 1.95 95% CI: 1.62, 2.35 <italic>I</italic><sup>2</sup> = 89%). The results remained unchanged on sensitivity and subgroup analyses based on study location, sample size, diagnosis, CONUT cutoff, and the Newcastle–Ottawa Scale score. Only six studies reported data on PFS, and the pooled analysis found that high CONUT was a significant marker for poor PFS in patients with hematological malignancies [hazards ratio (HR): 1.64 95% CI: 1.21, 2.20 <italic>I</italic><sup>2</sup> = 70%]. These results, too, maintained significance in the sensitivity analysis.</p></sec><sec id="sec4"><title>Conclusion</title><p>CONUT is an independent predictor of poor OS in patients with hematological malignancies. The results appear to be valid across different cancer types and with different CONUT cutoffs. Scarce data also suggest that CONUT could predict PFS.</p></sec>